// App-Quantinova.ai

2573 : Phase 1/2 study of oral rucaparib: Final phase 1 results.

Researchers

Presenter

  • Rebecca Sophie Kristeleit

Principal Investigators

  • Howard A. Burris

  • Patricia Lo Russo

  • Heidi Giordano

  • Jennifer Borrow

  • Sarah S. Jaw-Tsai

  • Fatima El-Khouly

  • Alan Hilary Calvert

  • Jeffrey R. Infante

  • John Frederick Hilton

  • Sara M. Tolaney

  • Muaiad Kittaneh

  • Geoffrey Shapiro

  • Manish R. Patel

  • Uzma Saddia Asghar

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Dana-Farber Cancer Institute, Boston, MAUniversity College London Cancer Institute, London, United KingdomFlorida Cancer Specialists and Research Institute, Sarasota, FL

  • Kings College London, London, United Kingdom

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Bart's Cancer Institute, London, United Kingdom

  • Clovis Onc, San Francisco, CA

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Clovis Oncology, Inc., Boulder, CO

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Rucaparib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01482715

Sponsors

  • Clovis Oncology

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved